Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

The Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and broader diversification than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has generated higher 1-year and 5-year total returns while maintaining lower price volatility.

The Motley Fool • Oct 11, 2026

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.

The Motley Fool • Oct 3, 2026

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • Sep 28, 2026

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks

The State Street Health Care Select Sector SPDR ETF (XLV) offers significantly lower ownership costs, with an expense ratio of 0.08% compared to 0.58% for the Invesco Pharmaceuticals ETF (PJP). PJP provides concentrated exposure to 28 pharmaceutical stocks, while XLV holds 61 diversified healthcare companies.

The Motley Fool • Sep 23, 2026

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Launched on June 23, 2005, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks Investment Research • Sep 3, 2026

FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?

Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of just over 30 pharmaceutical stocks, while FHLC diversifies across more than 300 holdings.

The Motley Fool • Aug 23, 2026

XPH vs PJP: Which Pharma ETF Offers Better Value

The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.

The Motley Fool • Aug 17, 2026

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Barrons • Aug 7, 2026

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excluding Japan was little changed after swinging between gains and losses.

Invezz • Jul 30, 2026

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

Vanguard Health Care ETF offers a lower expense ratio and higher dividend yield than Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has concentrated its portfolio in 29 pharmaceutical stocks whereas Vanguard Health Care ETF holds 411 healthcare companies Invesco Pharmaceuticals ETF significantly outperformed on a 1-year total return basis

The Motley Fool • Jul 22, 2026